Neurotoxic component of a botulinum toxin

Abstract

A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.

1 . A method for reducing a cholinergic influenced secretion, said method comprising administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin in order to reduce a cholinergic influenced secretion.  
     
     
         2 - 5 . (canceled)  
     
     
         6 . A method for treating a smooth muscle disorder, said method comprising administering to the patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin in order to treat a smooth muscle disorder.  
     
     
         7 - 13 . (canceled)  
     
     
         14 . A method for relieving a muscle spasm said method comprising administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin.  
     
     
         15 - 20 . (canceled)  
     
     
         21 . The method of  claim 1 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.  
     
     
         22 . The method of  claim 21 , wherein the botulinum toxin is a botulinum toxin type A.  
     
     
         23 . The method of  claim 6 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.  
     
     
         24 . The method of  claim 23 , wherein the botulinum toxin is a botulinum toxin type A.  
     
     
         25 . The method of  claim 14 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.  
     
     
         26 . The method of  claim 25 , wherein the botulinum toxin is a botulinum toxin type A.  
     
     
         27 . A neurotoxic component of a botulinum toxin for use in humans.  
     
     
         28 . The neurotoxic component of  claim 27 , wherein the neurotoxic component has a molecular weight of about 150 kilodaltons.  
     
     
         29 . The neurotoxic component of  claim 27 , wherein the neurotoxic component is selected from the group of consisting of botulinum toxin type A, B, C, D, E, F and G neurotoxic components.  
     
     
         30 . The neurotoxic component of  claim 29 , wherein the neurotoxic component is the neurotoxic component of a botulinum toxin type A.